You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.
Are you sure you want to leave?
Cancel
Vifor Pharma made a virtual splash at the 2020 ERA–EDTA Congress
Adapting to the state of lockdown imposed by COVID-19, the 2020 European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress went online. We were there to raise awareness about secondary hyperparathyroidism (SHPT) and chronic kidney disease–mineral and bone disorder (CKD–MBD) by running a virtual symposium and hosting a virtual booth. Access to online videos of the symposium and highlights about the booth are provided below.
The virtual symposium featured expert opinions on CKD–MBD management
Watch the teaser video now. For the full-length presentations, please see the link below.
Our symposium, which was entitled ‘Expert approaches to management across the CKD–MBD continuum’, gave attendees the opportunity to explore the latest expert opinions on managing SHPT in non-dialysis patients and controlling hyperphosphataemia in dialysis patients.
The symposium was chaired by Dr Smeeta Sinha* and included two presentations:
- Evolving opportunities to optimise SHPT management, by Professor Mario Cozzolino†
- Effective control of hyperphosphataemia: the phosphate–protein dilemma, by Professor Kamyar Kalantar-Zadeh‡
If you missed the symposium, you can watch it online right now.
The virtual booth raised awareness about SHPT and other CKD-related disorders
Our virtual booth was divided into three sections, raising awareness about:
- SHPT
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- CKD-associated pruritis
The SHPT section of the booth provided access to many of the features available on this website, allowing attendees to:
- Explore the pathogenesis of SHPT, along with new data on the relationships between parathyroid hormone (PTH) levels, fractures, vascular events and death, through the interactive disease awareness aid available in the Learn section of this website
- Download our booklets about the challenges of treating SHPT and KDIGO’s guidelines on the management of CKD–MBD, accessible on our Download page
- Watch our creative animation about the unmet needs of SHPT treatment, available via our Watch page
- Test their SHPT knowledge by taking our online SHPT Challenge, now available at SHPTchallenges.com
We’d like to extend our gratitude to all involved in delivering our booth and symposium, especially the Chair, Dr Sinha, and our distinguished speakers, professors Cozzolino and Kalantar-Zadeh.
Footnotes
*North West England Renal Network Chair; National Health Service; Manchester, United Kingdom.
†Director of Renal Unit and Laboratory of Experimental Nephrology; Department of Health Sciences, University of Milan; Milan, Italy.
‡Professor of Medicine; School of Medicine, University of California, Irvine; California, USA.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site's accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2021 Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology …
Read More
